Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
JANX

JANX - Janux Therapeutics, Inc. Stock Price, Fair Value and News

43.48USD-0.75 (-1.70%)Market Closed

Market Summary

JANX
USD43.48-0.75
Market Closed
-1.70%

JANX Stock Price

View Fullscreen

JANX RSI Chart

JANX Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-40.55

Price/Sales (Trailing)

120.28

Price/Free Cashflow

-42.33

JANX Price/Sales (Trailing)

JANX Profitability

Return on Equity

-8.48%

Return on Assets

-8.07%

Free Cashflow Yield

-2.36%

JANX Fundamentals

JANX Revenue

Revenue (TTM)

18.7M

Rev. Growth (Yr)

91.39%

Rev. Growth (Qtr)

-28.8%

JANX Earnings

Earnings (TTM)

-55.6M

Earnings Growth (Yr)

15.46%

Earnings Growth (Qtr)

-25.53%

Breaking Down JANX Revenue

Last 7 days

10.2%

Last 30 days

3.5%

Last 90 days

-14.0%

Trailing 12 Months

249.0%

How does JANX drawdown profile look like?

JANX Financial Health

Current Ratio

62.09

JANX Investor Care

Shares Dilution (1Y)

23.95%

Diluted EPS (TTM)

-1.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202418.7M000
20236.7M9.6M10.3M16.2M
20223.4M3.3M3.9M4.0M
20210003.6M

Tracking the Latest Insider Buys and Sells of Janux Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 26, 2024
simson jake
acquired
-
-
2,500
-
Jun 26, 2024
kung winston
acquired
-
-
2,500
-
Jun 26, 2024
mcnulty alana b.
acquired
-
-
2,500
-
Jun 26, 2024
gujrathi sheila
acquired
-
-
2,500
-
Jun 26, 2024
lichter jay
acquired
-
-
2,500
-
Jun 26, 2024
ra capital management, l.p.
acquired
-
-
2,500
-
Jun 26, 2024
barrett ronald w
acquired
-
-
2,500
-
Jun 26, 2024
capps vickie l
acquired
-
-
2,500
-
Jun 03, 2024
avalon ventures xi, l.p.
sold
-37,861,000
54.75
-691,525
-
Jun 03, 2024
lichter jay
sold
-37,081,000
54.75
-677,279
-

1–10 of 50

Which funds bought or sold JANX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
SG Americas Securities, LLC
new
-
1,452,000
1,452,000
0.01%
Jul 10, 2024
Fortitude Family Office, LLC
unchanged
-
877
8,671
-%
Jul 10, 2024
CWM, LLC
added
200
-
-
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
sold off
-100
-18,000
-
-%
Jul 05, 2024
DNB Asset Management AS
new
-
220,886
220,886
-%
Jul 02, 2024
GAMMA Investing LLC
added
38.89
369
1,047
-%
Jul 01, 2024
Legal & General Group Plc
added
63.01
500,405
606,428
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
1,298,000
1,877,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
82.35
309,824
366,824
0.05%
May 20, 2024
Virtu Financial LLC
new
-
609,000
609,000
0.05%

1–10 of 48

Are Funds Buying or Selling JANX?

Are funds buying JANX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own JANX
No. of Funds

Unveiling Janux Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 05, 2024
avalon ventures xi, l.p.
6.3%
3,271,216
SC 13D/A
Mar 06, 2024
ra capital management, l.p.
19.99%
10,593,395
SC 13D/A
Mar 04, 2024
avalon ventures xi, l.p.
7.7%
3,948,495
SC 13D/A
Feb 14, 2024
biotechnology value fund l p
5.3%
2,427,414
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
0%
0
SC 13G/A
Feb 14, 2024
citadel advisors llc
6.8%
6
SC 13G/A
Feb 09, 2024
campbell david alan
5.3%
2,545,075
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 01, 2024
bregua corp
8.3%
3,830,257
SC 13G/A
Nov 16, 2023
avalon ventures xi, l.p.
9.5%
4,387,217
SC 13D/A

Recent SEC filings of Janux Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
8-K
Current Report
Jun 17, 2024
DEFA14A
DEFA14A

Peers (Alternatives to Janux Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.6B
6.8B
-13.25% 0.10%
-7.8
6.8
-64.45% -224.75%
32.4B
2.0B
59.65% 29.92%
-97.54
16.17
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.1B
2.5B
1.33% -1.46%
78.21
6.5
13.74% 186.89%
14.4B
3.8B
3.45% 4.03%
19.35
3.83
8.58% 129.81%
MID-CAP
5.2B
107.9M
- 52.91%
-9.54
48.09
54.84% -28.31%
4.9B
524.1M
-4.71% -52.64%
-11.64
9.27
394.93% 39.61%
3.9B
251.0M
12.43% 12.43%
-13.27
15.66
73.58% -86.73%
3.6B
240.7M
11.69% -16.59%
-7.58
12.77
-1.03% -213.92%
3.0B
813.8M
21.06% -43.91%
-1.7K
3.66
56.43% 98.83%
2.1B
996.6M
5.00% 74.19%
-5.32
2.13
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.22% 30.25%
30.38
4.81
60.38% -34.49%
632.3M
881.7K
18.10% 671.45%
-18.73
481.06
-77.61% 33.36%
286.3M
4.2M
21.56% 73.74%
-2.29
68.83
-66.30% 48.24%
19.8M
2.1M
-10.16% -79.46%
-0.86
7.61
-13.45% 69.54%

Janux Therapeutics, Inc. News

Latest updates
MarketBeat30 hours ago

Janux Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue-28.8%5,4017,5862,5173,2402,8221,7141,8133731321,6161,159482380
Operating Expenses15.1%21,41318,59818,33021,80522,32921,11119,83519,62615,13115,10612,0626,7342,664
  S&GA Expenses15.5%7,3436,3576,4386,8816,4645,6776,0985,5404,9473,9373,6561,997739
  R&D Expenses14.9%14,07012,24111,89214,92415,86515,43413,73714,08610,18411,1698,4064,7371,925
Net Income-25.5%-14,760-11,758-11,568-17,508-17,459-16,065-16,696-16,888-13,410-13,416-10,766-6,206-2,284
Net Income Margin17.8%-2.97*-3.61*-6.08*-7.06*-9.98*-15.64*-15.36*-16.61*-12.92*-8.98*---
Free Cashflow-44.3%-15,034-10,416-12,179-15,634-14,196-13,969-15,934-6,971-12,493-11,654-5,931-6,2835,410
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets81.1%689380387342353364376385369380391397-
  Current Assets88.6%65934935530932133234435836537739039716.00
    Cash Equivalents1008.1%21319.0017.0034.0030.0051.0065.0058.0055.0036.0039.002528.00
  Net PPE-6.9%7.007.007.007.007.007.007.004.003.001.001.000.000.00
Liabilities-7.9%33.0036.0038.0042.0042.0043.0044.0042.0013.0013.0014.0012.009.00
  Current Liabilities-18.6%11.0013.0014.0018.0016.0017.0016.0013.0013.0013.0012.009.003.00
Shareholder's Equity90.4%656344349299311321332344356366377385-
  Retained Earnings-8.7%-183-168-157-145-127-110-94.40-77.71-60.82-47.41-34.00-23.20-14.74
  Additional Paid-In Capital63.9%8405125074464404334284234184144114080.00
Shares Outstanding12.1%52.0046.0046.0042.0042.0042.0041.0041.0041.0041.0018.006.00-
Float----280---205---526-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-49.9%-14,837-9,901-11,709-15,054-13,911-11,913-13,414-6,073-11,522-10,481-5,854-6,2045,563---
  Share Based Compensation25.5%5,6254,4834,5485,5015,4734,2054,5964,4443,9582,9442,5661,277123-28.002.00
Cashflow From Investing-1122.5%-113,73611,123-61,45117,874-8,740-1,60419,7639,03931,0687,326-205,539-142,597-153---
Cashflow From Financing38669.1%322,17183156,6095281,580191-3081.00164-843329,65757,546---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

JANX Income Statement

2024-03-31
Unaudited Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 1,252$ 2,048
Operating expenses:  
Research and development14,07015,865
General and administrative7,3436,464
Total operating expenses21,41322,329
Loss from operations(20,161)(20,281)
Other income:  
Interest income5,4012,822
Total other income5,4012,822
Net loss(14,760)(17,459)
Other comprehensive gain (loss):  
Unrealized gain (loss) on available-for-sale securities, net(1,189)796
Comprehensive loss$ (15,949)$ (16,663)
Net loss per common share, basic$ (0.3)$ (0.42)
Net loss per common share, diluted$ (0.3)$ (0.42)
Weighted-average shares of common stock outstanding, basic49,049,74141,763,971
Weighted-average shares of common stock outstanding diluted49,049,74141,763,971

JANX Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 212,803$ 19,205
Accounts receivable5190
Short-term investments438,960324,823
Prepaid expenses and other current assets6,3845,213
Total current assets658,666349,241
Restricted cash816816
Property and equipment, net6,5177,003
Operating lease right-of-use assets20,46120,838
Other long-term assets2,5242,509
Total assets688,984380,407
Current liabilities:  
Accounts payable2,2542,424
Accrued expenses5,8107,387
Current portion of deferred revenue9721,705
Current portion of operating lease liabilities1,5731,517
Total current liabilities10,60913,033
Operating lease liabilities, net of current portion22,61223,025
Total liabilities33,22136,058
Commitments and contingencies (Note 3)
Stockholders’ equity (deficit):  
Preferred stock, $0.001 par value; authorized shares -10,000,000 at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value; authorized shares - 200,000,000 at March 31, 2024 and December 31, 2023, respectively; issued shares - 51,846,342 and 46,262,759 at March 31, 2024 and December 31, 2023, respectively; outstanding shares - 51,840,571 and 46,252,440 at March 31, 2024 and December 31, 2023, respectively5146
Additional paid-in capital839,759512,401
Accumulated other comprehensive income (loss)(524)665
Accumulated deficit(183,523)(168,763)
Total stockholders' equity655,763344,349
Total liabilities and stockholders' equity$ 688,984$ 380,407
JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
 CEO
 WEBSITEjanuxrx.com
 INDUSTRYBiotechnology
 EMPLOYEES67

Janux Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Janux Therapeutics, Inc.? What does JANX stand for in stocks?

JANX is the stock ticker symbol of Janux Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Janux Therapeutics, Inc. (JANX)?

As of Mon Jul 15 2024, market cap of Janux Therapeutics, Inc. is 2.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers. The fair value of Janux Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Janux Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JANX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Janux Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JANX is over valued or under valued. Whether Janux Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Janux Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JANX.

What is Janux Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jul 15 2024, JANX's PE ratio (Price to Earnings) is -40.55 and Price to Sales (PS) ratio is 120.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JANX PE ratio will change depending on the future growth rate expectations of investors.